Gedeon Richter has announced that a filing for its RGB-19 Mochida-partnered biosimilar rival to RoActemra (tocilizumab) has been accepted for review by the European Medicines Agency. “The submission o
Tolebrutinib, Sanofi’s investigational treatment for non-relapsing secondary progressive multiple sclerosis (nrSPMS), is among the latest products that the European Medicines Agency has started review
Gedeon Richter championed the impact of its recent European launches of generic versions of Bayer’s Xarelto (rivaroxaban) and Boehringer Ingelheim’s Pradaxa (dabigatran), as its total Pharma revenues
Japan’s Mochida Pharmaceutical has confirmed plans to file its Gedeon Richter-partnered RGB-19 biosimilar tocilizumab candidate in Japan after achieving positive topline results from Phase I and Phase